HIV

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.

PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.

The theme of this year’s National HIV Testing Day encourages individuals to self-test for HIV as a means of demonstrating their compassion for themselves.

Check out these top featured stories from Drug Topics in June 2024.

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

The new approval is supported by the phase 3 Study 4030, which evaluated the efficacy, safety, and tolerability profile of Biktarvy in a broad range of people with HIV-1 with or without pre-existing NRTI resistance, including those with the M184V/I resistance.

Participants of a recent study who received automated text messaging and monitoring, as well as peer support and coaching, increased PrEP uptake from 11% to over 20%.

Study results highlight the potential of blood-based markers in understanding neurological conditions.

Abacavir/dolutegravir/lamivudine is a fixed-dose combination containing two nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitor (INSTI).

Previously hepatitis B vaccines have offered lower levels of protection for people living with HIV. New research indicates that a 3-dose series could offer much better protection.

Researchers speculate that the disparities among those with private insurance coverage may reflect differences in overcoming hurdles to access, such as prior authorization.

Lenacapavir was approved with the FDA's Breakthrough Therapy Designation.

About 40% of people monkeypox also had HIV, according to a CDC study that included almost 2000 monkeypox cases in the United States that occurred during the first 2 months of the outbreak.

The risk of breakthrough was higher in people living with HIV regardless of CD4 count or HIV viral suppression, according to findings reported by researchers at Johns Hopkins.

PrEP is an effective way to fight HIV transmission, and more pharmacies are providing this important service.

Results address the concern that COVID-19 vaccination might not be effective among those living with HIV.

Results of a recent preclinical study provide proof of concept that an mRNA HIV vaccine is safe, immunogenic, and induces CD4–T-cell responses.

Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.

Apretude is approved for use in at-risk adults and adolescent to reduce the risk of sexually acquired HIV.

Starting February 11, federal vaccine supplies will be delivered directly to select pharmacies, according to the announcement.

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Both trial sub-analyses will be presented at the virtual 23rd International AIDS Conference.

Survey results on PrEP access and utilization during COVID-19 shelter-in-place orders presented at the 23rd International AIDS Conference.

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.

Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.

Virtual care takes center stage amid the pandemic.

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV.